Please see below to view the coverage details for this session entry.

Wednesday, October 24


Benefits, Risks, and Cost Effectiveness of Lung Cancer Screening: Do We Know Enough?

After many years of expensive and largely ineffective clinical trials focused on trying to reduce morbidity and mortality from lung cancer, the National Lung Screening Trial showed a substantial reduction in lung cancer-specific mortality from screening with CT.  While the primary study hypotheses and results were published over a year ago, debate still continues about whether we have a sufficient picture of all aspects of benefits, risks, and cost-effectiveness in order to make policy decisions.  This presentation will review the state of our knowledge and describe what decisions at an individual, population, and policy level may make sense at this time while we wait for further critical analyses from NLST.

Wednesday October 24, 2012 10:45am - 11:30am
Glass Oaks (9721 Arboretum Boulevard, Austin, TX 78759)

Larry Kessler, ScD

Professor and Chair, Department of Health Services, University of Washington